Thetis Pharmaceuticals LLC
Southport, US · Founded 2011 · Connecticut LLC · 2 known investors
Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance. It is being developed for inflammatory bowel disease, including ulcerative colitis, and solid tumors.
Founders & leadership
Thetis Pharmaceuticals LLC was founded in 2011 by Frank C Sciavolino and Gary Mathias.
FC
Frank C SciavolinoManager
GM
Gary MathiasCo-Founder & CEO
JP
John ParkinsonChief Science Officer
JS
Joyce SteinbergChief Medical Officer
Board
DM
David M WurzerManager
AM
Alan MendelsonManager
DW
Dennis WillsonManager
Investors · 2
Also in the syndicate · 1
Helmsley Charitable Trust
Reported raises · per SEC filings
Form D private placements$7.4M disclosed across 4 of 5 rounds · 2016–2025
▶$1.1MraisedJul 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJul 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary MathiasExecutive Officer, Director
- Frank C. SciavolinoDirector
- Walter OgierDirector
- Cynthia GreenDirector
- Dennis F. WillsonDirector
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- First sale
- Jun 2022
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$795.8KraisedAug 2018 · 8 investors · PharmaceuticalsRule 506(b)
▶$795.8KraisedAug 2018 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David M WurzerDirector
- Frank C SciavolinoExecutive Officer, Director
- Dennis F WillsonDirector
- Gary MathiasExecutive Officer, Director
- Walter OgierDirector
- Offering amount
- $2.1M
- Amount sold
- $795.8K
- First sale
- Aug 2018
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$4.1MraisedJan 2017 · 52 investors · PharmaceuticalsRule 506(b)
▶$4.1MraisedJan 2017 · 52 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis F WillsonDirector
- David M WurzerDirector
- Gary F MathiasExecutive Officer, Director
- Frank C SciavolinoExecutive Officer, Director
- Walter OgierDirector
- Offering amount
- $8M
- Amount sold
- $4.1M
- Sales commissions
- $200K
- Placement agents
- Fairport Capital, Inc.
- First sale
- Jun 2016
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$1.4MraisedFeb 2016 · 16 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedFeb 2016 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary F MathiasExecutive Officer, Director
- Dennis WillsonDirector
- David M WurzerDirector
- Frank C SciavolinoDirector
- Alan MendelsonDirector
- Offering amount
- $4M
- Amount sold
- $1.4M
- First sale
- Jan 2016
- Incorporated
- Limited Liability Company, Connecticut, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Fortis Life Sciences16 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Zentalis11 shared keywordsZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Companies competing with Thetis Pharmaceuticals LLC for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $997.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $398.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $295.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $293.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $205.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $206K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Thetis Pharmaceuticals LLC do?
- Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance. It is being developed for inflammatory bowel disease, including ulcerative colitis, and solid tumors.
- Who founded Thetis Pharmaceuticals LLC?
- Thetis Pharmaceuticals LLC was founded by Frank C Sciavolino, Gary Mathias in 2011.
- Who are Thetis Pharmaceuticals LLC's investors?
- Thetis Pharmaceuticals LLC's investors include Connecticut Innovations.
- How much funding has Thetis Pharmaceuticals LLC raised?
- Thetis Pharmaceuticals LLC has disclosed $7.4M raised across 4 of its 5 known rounds.
- Where is Thetis Pharmaceuticals LLC headquartered?
- Thetis Pharmaceuticals LLC is headquartered in Southport, US.